{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:48:59Z","timestamp":1791978539413,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.bcp.2020.113829","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T19:54:30Z","timestamp":1580154870000},"page":"113829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7)"],"prefix":"10.1016","volume":"174","author":[{"given":"Sumathy","family":"Mathialagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-an","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester","family":"Costales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9701-756X","authenticated-orcid":false,"given":"Amit S.","family":"Kalgutkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. David","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manthena V.S.","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2020.113829_b0005","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/jpet.107.120758","article-title":"NAD+ and vitamin B3: from metabolism to therapies","volume":"324","author":"Sauve","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2020.113829_b0010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch. Biochem. Biophys."},{"issue":"12a","key":"10.1016\/j.bcp.2020.113829_b0015","doi-asserted-by":"crossref","first-page":"51l","DOI":"10.1016\/S0002-9149(00)01471-5","article-title":"Evaluating niacin in its various forms","volume":"86","author":"Knopp","year":"2000","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2020.113829_b0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1074248413514481","article-title":"The therapeutic role of niacin in dyslipidemia management","volume":"19","author":"Boden","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"25","key":"10.1016\/j.bcp.2020.113829_b0025","doi-asserted-by":"crossref","first-page":"18028","DOI":"10.1074\/jbc.M701866200","article-title":"Nicotinic acid receptor agonists differentially activate downstream effectors","volume":"282","author":"Richman","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"8a","key":"10.1016\/j.bcp.2020.113829_b0030","doi-asserted-by":"crossref","first-page":"20b","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2020.113829_b0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOL.0b013e3283613a68","article-title":"Recent advances in niacin and lipid metabolism","volume":"24","author":"Kamanna","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"issue":"4","key":"10.1016\/j.bcp.2020.113829_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040974","article-title":"Niacin in the central nervous system: an update of biological aspects and clinical applications","volume":"20","author":"Gasperi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2020.113829_b0045","doi-asserted-by":"crossref","first-page":"C1773","DOI":"10.1152\/ajpcell.00409.2007","article-title":"Mechanism of nicotinic acid transport in human liver cells: experiments with HepG2 cells and primary hepatocytes","volume":"293","author":"Said","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"12","key":"10.1016\/j.bcp.2020.113829_b0050","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1124\/dmd.109.028654","article-title":"Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs","volume":"37","author":"Ahlin","year":"2009","journal-title":"Drug Metab. Disposition Biol. Fate Chem."},{"issue":"9","key":"10.1016\/j.bcp.2020.113829_b0055","doi-asserted-by":"crossref","first-page":"G601","DOI":"10.1152\/ajpgi.00231.2013","article-title":"Recent advances in transport of water-soluble vitamins in organs of the digestive system: a focus on the colon and the pancreas","volume":"305","author":"Said","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"24","key":"10.1016\/j.bcp.2020.113829_b0060","doi-asserted-by":"crossref","first-page":"16332","DOI":"10.1074\/jbc.M800737200","article-title":"Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13)","volume":"283","author":"Bahn","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2020.113829_b0065","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2133\/dmpk.20.452","article-title":"Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies","volume":"20","author":"Nishimura","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.bcp.2020.113829_b0070","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1208\/s12248-017-0051-2","article-title":"Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes","volume":"19","author":"Bi","year":"2017","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.bcp.2020.113829_b0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.119.257600","article-title":"Quantitative contribution of six major transporters to the hepatic uptake of drugs: \u201cSLC-phenotyping\u201d using primary human hepatocytes","volume":"370","author":"Bi","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2020.113829_b0080","doi-asserted-by":"crossref","first-page":"F843","DOI":"10.1152\/ajprenal.00140.2015","article-title":"Human organic anion transporter 2 is distinct from organic anion transporters 1 and 3 with respect to transport function","volume":"309","author":"Henjakovic","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2020.113829_b0085","first-page":"1284","article-title":"Role of hepatic organic anion transporter 2 in the pharmacokinetics of R- and S-warfarin","volume":"15","author":"Bi","year":"2018","journal-title":"Vitro Stud. Mech. Eval. Mol. Pharm."},{"key":"10.1016\/j.bcp.2020.113829_b0090","first-page":"1","article-title":"In vitro studies with two human organic anion transporters: OAT2 and OAT7","author":"Mathialagan","year":"2017","journal-title":"Xenobiotica"},{"issue":"8","key":"10.1016\/j.bcp.2020.113829_b0095","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0026-0495(92)90170-F","article-title":"Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action?","volume":"41","author":"Stern","year":"1992","journal-title":"Metab. Clin. Exp."},{"issue":"12 Suppl","key":"10.1016\/j.bcp.2020.113829_b0100","first-page":"S308","article-title":"Understanding niacin formulations","volume":"8","author":"Pieper","year":"2002","journal-title":"Am. J. Manage. Care"},{"key":"10.1016\/j.bcp.2020.113829_b0105","series-title":"Handbook of Experimental Pharmacology","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-642-14541-4_2","article-title":"In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy","author":"Burckhardt","year":"2011"},{"issue":"8","key":"10.1016\/j.bcp.2020.113829_b0110","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1002\/jcp.26409","article-title":"The role of OAT2 (SLC22A7) in the cyclic nucleotide biokinetics of human erythrocytes","volume":"233","author":"Sager","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2020.113829_b0115","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1124\/jpet.117.245951","article-title":"Organic anion transporter 2 mediates hepatic uptake of tolbutamide, a CYP2C9 probe drug","volume":"364","author":"Bi","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2020.113829_b0120","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","article-title":"Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS)","volume":"32","author":"Varma","year":"2015","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.bcp.2020.113829_b0125","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.118.252049","article-title":"Organic anion transporter 2-mediated hepatic uptake contributes to the clearance of high-permeability-low-molecular-weight acid and zwitterion drugs: evaluation using 25 drugs","volume":"367","author":"Kimoto","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.113829_b0130","article-title":"Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in non-alcoholic fatty liver disease","author":"Vildhede","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2020.113829_b0135","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5414\/CPP45448","article-title":"Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation","volume":"45","author":"Menon","year":"2007","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2020.113829_b0140","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ndt\/gfq344","article-title":"Pharmacokinetics and dose recommendations of Niaspan(R) in chronic kidney disease and dialysis patients","volume":"26","author":"Reiche","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.bcp.2020.113829_b0145","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/dmd.116.072264","article-title":"Organic anion transporter 2: an enigmatic human solute carrier","volume":"45","author":"Shen","year":"2017","journal-title":"Drug Metab. Disposit."},{"issue":"1","key":"10.1016\/j.bcp.2020.113829_b0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by organic anion transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2020.113829_b0155","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacl.2019.10.006","article-title":"Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?","volume":"13","author":"Kashyap","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"1","key":"10.1016\/j.bcp.2020.113829_b0160","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41598-018-38002-7","article-title":"Dietary niacin intake predicts the decrease of liver fat content during a lifestyle intervention","volume":"9","author":"Linder","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2020.113829_b0165","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/j.1523-1755.2005.00612.x","article-title":"Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]","volume":"68","author":"Xu","year":"2005","journal-title":"Kidney Int."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2020.113829_b0170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2009.10.015","article-title":"Identification of genetic polymorphisms of human OAT1 and OAT2 genes and their relationship to hOAT2 expression in human liver","volume":"411","author":"Shin","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bcp.2020.113829_b0175","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fphar.2015.00216","article-title":"Organic anion transporter 2 transcript variant 1 shows broad ligand selectivity when expressed in multiple cell lines","volume":"6","author":"Hotchkiss","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2020.113829_b0180","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4065\/mcp.2009.0535","article-title":"A \u201chot\u201d topic in dyslipidemia management\u2013\u201chow to beat a flush\u201d: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention","volume":"85","author":"Jacobson","year":"2010","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.bcp.2020.113829_b0185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"issue":"5","key":"10.1016\/j.bcp.2020.113829_b0190","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans","volume":"98","author":"Morrow","year":"1992","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"10.1016\/j.bcp.2020.113829_b0195","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Benyo","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.bcp.2020.113829_b0200","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2020.113829_b0205","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacl.2007.04.003","article-title":"The role of nicotinic acid metabolites in flushing and hepatotoxicity","volume":"1","author":"Stern","year":"2007","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.bcp.2020.113829_b0210","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jconrel.2005.09.054","article-title":"Characterization of the transdermal transport of flurbiprofen and indomethacin","volume":"110","author":"Li","year":"2006","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2020.113829_b0215","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jconrel.2007.08.019","article-title":"Involvement of organic anion transport system in transdermal absorption of flurbiprofen","volume":"124","author":"Ito","year":"2007","journal-title":"J. Control. Release"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220300393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220300393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:12:05Z","timestamp":1757769125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220300393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":43,"alternative-id":["S0006295220300393"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113829","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7)","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113829"}}